Central Nervous System Metastases from Triple-Negative Breast Cancer: Current Treatments and Future Prospective

被引：26
作者：
Syriac, Arun Kadamkulam [1 ]
Nandu, Nitish Singh [2 ]
Leone, Jose Pablo [1 ]
机构：
[1] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02215 USA
[2] Montefiore Med Ctr, Albert Einstein Coll Med, Dept Hosp & Palliat Med, Bronx, NY 10467 USA
来源：
BREAST CANCER-TARGETS AND THERAPY | 2022年 / 14卷
关键词：
triple-negative breast cancer; metastatic disease; brain metastasis; prognosis clinical outcomes; immunotherapy; stereotactic radiosurgery; whole-brain radiation therapy; antibody-drug conjugate; oligometastatic brain metastasis; clinical outcomes; prediction; prognosis; personalization; multi-omics; machine learning; individualized treatment algorithms; patient benefits; WHOLE-BRAIN RADIOTHERAPY; GRADED PROGNOSTIC ASSESSMENT; PHASE-III TRIAL; FRONT-LINE CHEMOTHERAPY; CELL LUNG-CARCINOMA; SACITUZUMAB GOVITECAN; SURGICAL RESECTION; MALIGNANT-MELANOMA; DOUBLE-BLIND; CAPECITABINE;
D O I：
10.2147/BCTT.S274514
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
It is estimated that approximately one-third of patients with triple-negative breast cancer (TNBC) will develop brain metastases. The prognosis for patients with breast cancer brain metastasis has improved in the recent past, especially for hormone receptor and human epidermal growth factor receptor 2 (HER) positive subtypes. However, the overall survival rate for patients with triple-negative subtype remains poor. The development of newer treatment options, including antibody-drug conjugates such as Sacituzumab govitecan, is particularly encouraging. This article reviews the clinical outcomes, challenges, and current approach to the treatment of brain metastasis in TNBC. We have also briefly discussed newer treatment options and ongoing clinical trials. The development of brain metastasis significantly decreases the quality of life of patients with TNBC, and newer treatment strategies and therapeutics are the need of the hour for this disease subgroup.
引用
收藏
页码：1 / 13
页数：13
相关论文
共 106 条
  • [1] Brain metastases
    Achrol, Achal Singh
    Rennert, Robert C.
    Anders, Carey
    Soffietti, Riccardo
    Ahluwalia, Manmeet S.
    Nayak, Lakshmi
    Peters, Solange
    Arvold, Nils D.
    Harsh, Griffith R.
    Steeg, Patricia S.
    Chang, Steven D.
    [J]. NATURE REVIEWS DISEASE PRIMERS, 2019, 5 (1)
  • [2] Frame-based radiosurgery of multiple metastases using single-isocenter volumetric modulated arc therapy technique
    Ahn, Kang-Hyun
    Yenice, Kamil M.
    Koshy, Matthew
    Slavin, Konstantin, V
    Aydogan, Bulent
    [J]. JOURNAL OF APPLIED CLINICAL MEDICAL PHYSICS, 2019, 20 (08): : 21 - 28
  • [3] Metastatic disease in the cerebellum - The LSU experience in 1981-1993
    Ampil, FL
    Nanda, A
    Willis, BK
    Nandy, I
    Meehan, R
    [J]. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 1996, 19 (05): : 509 - 511
  • [4] TBCRC 018: phase II study of iniparib in combination with irinotecan to treat progressive triple negative breast cancer brain metastases
    Anders, Carey
    Deal, Allison M.
    Abramson, Vandana
    Liu, Minetta C.
    Storniolo, Anna M.
    Carpenter, John T.
    Puhalla, Shannon
    Nanda, Rita
    Melhem-Bertrandt, Amal
    Lin, Nancy U.
    Marcom, P. Kelly
    Van Poznak, Catherine
    Stearns, Vered
    Melisko, Michelle
    Smith, J. Keith
    Karginova, Olga
    Parker, Joel
    Berg, Jonathan
    Winer, Eric P.
    Peterman, Amy
    Prat, Aleix
    Perou, Charles M.
    Wolff, Antonio C.
    Carey, Lisa A.
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2014, 146 (03) : 557 - 566
  • [5] [Anonymous], 2018, FDA approves talazoparib for gBRCAm HER2-negative locally advanced or metastatic breast cancer
  • [6] Neratinib Plus Paclitaxel vs Trastuzumab Plus Paclitaxel in Previously Untreated Metastatic ERBB2-Positive Breast Cancer The NEfERT-T Randomized Clinical Trial
    Awada, Ahmad
    Colomer, Ramon
    Inoue, Kenichi
    Bondarenko, Igor
    Badwe, Rajendra A.
    Demetriou, Georgia
    Lee, Soo-Chin
    Mehta, Ajay O.
    Kim, Sung-Bae
    Bachelot, Thomas
    Goswami, Chanchal
    Deo, Suryanarayan
    Bose, Ron
    Wong, Alvin
    Xu, Feng
    Yao, Bin
    Bryce, Richard
    Carey, Lisa A.
    [J]. JAMA ONCOLOGY, 2016, 2 (12) : 1557 - 1564
  • [7] Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study
    Bachelot, Thomas
    Romieu, Gilles
    Campone, Mario
    Dieras, Veronique
    Cropet, Claire
    Dalenc, Florence
    Jimenez, Marta
    Le Rhun, Emilie
    Pierga, Jean-Yves
    Goncalves, Anthony
    Leheurteur, Marianne
    Domont, Julien
    Gutierrez, Maya
    Cure, Herve
    Ferrero, Jean-Marc
    Labbe-Devilliers, Catherine
    [J]. LANCET ONCOLOGY, 2013, 14 (01) : 64 - 71
  • [8] Treatment strategies for breast cancer brain metastases
    Bailleux, Caroline
    Eberst, Lauriane
    Bachelot, Thomas
    [J]. BRITISH JOURNAL OF CANCER, 2021, 124 (01) : 142 - 155
  • [9] ASCENT: A randomized phase III study of sacituzumab govitecan (SG) vs treatment of physician's choice (TPC) in patients (pts) with previously treated metastatic triple-negative breast cancer (mTNBC)
    Bardia, A.
    Tolaney, S. M.
    Loirat, D.
    Punie, K.
    Oliveira, M.
    Rugo, H. S.
    Brufsky, A.
    Kalinsky, K.
    Cortes, J.
    O'Shaughnessy, J.
    Dieras, V. C.
    Carey, L. A.
    Gianni, L.
    Piccart, M.
    Loibl, S.
    Goldenberg, D.
    Hong, Q.
    Olivo, M. S.
    Itri, L. M.
    Hurvitz, S. A.
    [J]. ANNALS OF ONCOLOGY, 2020, 31 : S1149 - S1150
  • [10] Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the metropolitan Detroit cancer surveillance system
    Barnholtz-Sloan, JS
    Sloan, AE
    Davis, FG
    Vigneau, FD
    Lai, P
    Sawaya, RE
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 2865 - 2872
12345678910